Reply: To PMID 23624205.

  • Paul Tk Chew
  • Published 2013 in Journal of the American College of Cardiology


The problem of inaccessibility to quinidine, as bad as it is (1), is likely to get worse in the near future. The problem started when AstraZeneca discontinued its production in 2006 (2,3). Now, a subcontractor of Sanofi-Aventis, the sole producer of hydroquinidine, discontinued production of this valuable medication. Available supplies of hydroquinidine… (More)
DOI: 10.1016/j.jacc.2013.05.004


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics